On May 20, Roivant Sciences rose 11.1% in regular trading, trading at $30.54/share, with trading volume of approximately $35.74 million. The rally was driven by the company's disclosure of fiscal fourth-quarter and full-year financial results alongside business progress updates.

The company reported fiscal Q4 earnings per share from continuing operations of $0.28. Revenue came in at $2.52 million, missing the consensus estimate of $3.82 million. Despite the revenue shortfall, the simultaneous release of business development updates received a strongly positive market reaction, pushing shares higher from pre-market through regular trading hours.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease. The company operates through its Vant model, building focused subsidiaries to accelerate transformative drug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)